Health Professionals ▶MUSC Online Videos Home ▶Course Catalog▶ Course Details
Course Details
Course Title Asthma 2025
Presented Date 03/15/2025
Expiration Date 03/14/2028
Presenter(s) Charlie Strange, M.D.
This Presenter does have relevant Financial Relationships to disclose.
   Research Grants - LAM Foundation, NIH, Department of Defense, CSA Medical, Dicerna, Grifols, Nuvaira,Pandorum, Takeda and Vertex
   Consultant - Alpha-1 Foundation AstraZeneca, GlaxoSmithKline, Inhibrix, Morair and Roche
   Other Medical Director - AlphaNet and Pulmanage
   Other Receives royalties - UpToDate
This activity was not supported by an education grant or any in-kind support.

The Medical University of South Carolina designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Description This video is part of the Therapy Update in Primary Care conference.
Objectives Competent with establishing an accurate diagnosis of asthma.
Recognize why albuterol is less favored than an ICS containing reliever medication for asthma.
Discuss triggers for initiation of biologic therapy for asthma.
Step 1
Watch the course video.
Step 2
1. The below link will take you to the CME Tracker Publisher Portal. Please make sure that the settings on your computer, tablet or phone allows for "pop-ups"
2. Sign in (or create an account) to generate certificate
3. The activity code will self-populate, click “Submit”
4. A pop-up box will appear that says “This activity has a required test” click “ok”
5. Complete the quiz. You will need to score 100%. You can retake the quiz as many times as necessary.
6. After completing the quiz, click “Continue” and “ok” when the score of 100% appears
7. Complete the evaluation and then “Submit”
8. Print or save your credit letter

CME Tracker - Claim Credit

Help

If you experience technical or accessibility issues, have questions about CME webcasting, or need assistance with webcast CME credit, please email us.